TIPARP and breast carcinoma: AHR has also been shown to repress IFN-I independently of PARP7 by inducing the proteolytic degradation of STING, and pharmacologic inhibition of AHR using BAY2416964 restored STING activity in breast cancer cell lines [31, 32].